Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study

1 October 2006

journal article
Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science

Vol. 47 (10), 4569-4578
https://doi.org/10.1167/iovs.06-0433

Abstract

Purpose. To evaluate the safety of three dose regimens of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the management of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Cited by 124 articles